` WGS (GeneDx Holdings Corp) vs S&P 500 Comparison - Alpha Spread

WGS
vs
S&P 500

Over the past 12 months, WGS has significantly outperformed S&P 500, delivering a return of +84% compared to the S&P 500's +14% growth.

Stocks Performance
WGS vs S&P 500

Loading
WGS
S&P 500
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
WGS vs S&P 500

Loading
WGS
S&P 500
Difference
www.alphaspread.com

Performance By Year
WGS vs S&P 500

Loading
WGS
S&P 500
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
GeneDx Holdings Corp vs Peers

No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

GeneDx Holdings Corp
Glance View

GeneDx Holdings Corp. holds a prominent spot in the realm of genetic testing and diagnostics, intertwining advanced technology with healthcare to create a substantial impact in personalized medicine. Originally founded with the mission to provide accessible genetic testing services, the company has evolved into a pivotal player in identifying rare genetic disorders through its specialized sequencing techniques. By leveraging next-generation sequencing (NGS), GeneDx can efficiently decode vast arrays of genetic information, enabling healthcare providers to diagnose and manage hereditary conditions more accurately. Their comprehensive test offerings cover everything from whole exome sequencing to disease-specific panels, catering to the needs of patients and clinicians alike. This tailored approach not only drives innovation but also establishes a firm foundation in genetic diagnostics, addressing some of the most pressing needs in modern medicine. In terms of revenue generation, GeneDx’s business model thrives on its collaborations with healthcare institutions, insurers, and research organizations. The company's ability to reduce the time and cost involved in traditional diagnostics creates a clear value proposition, encouraging widespread adoption of its services. Insurance reimbursements play a crucial role, as more healthcare policies expand to include genetic testing due to its significant potential for early disease detection and management. Moreover, strategic partnerships and continuous investments in research and development allow GeneDx to stay at the forefront of genomic insights, further strengthening its market position. By staying ahead of industry trends and focusing on expanding access to genetic information, GeneDx establishes itself not only as a leader in diagnostics but also as an integral force in the broader healthcare ecosystem, ensuring sustained growth and relevance.

WGS Intrinsic Value
38.75 USD
Overvaluation 72%
Intrinsic Value
Price
Back to Top